Huazhong Univ. of Sci. & Tech. – Tongji Medical College
华中科技大学同济医学院
Hospitals that carry this university's name, added together, plus papers and trials that name only the university.
Research activity, not treatment quality. Not medical advice. How this works
Nasopharyngeal carcinoma
鼻咽癌Led 24 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (23.4%).
- Open trials led
- 1
- Research papers it led
- 24
- Trials it led
- 4
- Share of China's trials
- 0.7%
- Share of the world's papers
- 0.7%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Retrospective study of a novel hematological parameter for predicting the survival of patients with nasopharyngeal carcinoma.
- Modulation Effects of the CEP128 Gene on Radiotherapy-Related Brain Injury: A Longitudinal Structural Study Using Multi-Parametric Brain MR Images.
- Nomograms incorporating primary tumor response at mid-radiotherapy to predict survival in locoregionally advanced nasopharyngeal carcinoma.
- Tumor factors associated with in-field failure for nasopharyngeal carcinoma after intensity-modulated radiotherapy.
- Long-term Therapeutic Outcome and Prognostic Factors of Patients with Nasopharyngeal Carcinoma Receiving Intensity-modulated Radiotherapy: An Analysis of 608 Patients from Low-endemic Regions of China.
Trials on ClinicalTrials.gov6
- Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma
- Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma
- Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
- QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
- A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
- Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 20 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.9%).
- Open trials led
- 3
- Research papers it led
- 20
- Trials it led
- 7
- Share of China's trials
- 1.2%
- Share of the world's papers
- 0.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Organ preservation in esophageal cancer treatment, is it time now?
- The crossroads of inflammation and nutrition: predicting neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma patients.
- Clinical efficacy and biomarkers of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma.
- Neoadjuvant chemoradiotherapy plus sequential tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): A single-arm, bicentric, phase 2 trial.
- CT-based delta-radiomics for predicting pathological response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma: a multicenter study.
Trials on ClinicalTrials.gov6
- Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC
- Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy
- Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma
- A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- Postoperative Radiotherapy and Lymph Node Dissection After Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
- Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Hepatocellular carcinoma
肝细胞癌Led 413 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (5.5%).
- Open trials led
- 29
- Research papers it led
- 413
- Trials it led
- 63
- Share of China's trials
- 4.3%
- Share of the world's papers
- 1.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial.
- A Randomized Comparison of Transradial and Transfemoral Approach in Hepatic Arterial Infusion Chemotherapy.
- Machine learning methods for accurately predicting survival and guiding treatment in stage I and II hepatocellular carcinoma.
- Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
- E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression.
Trials on ClinicalTrials.gov6
- AI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation
- Denosumab Strategy for Liver Cancer With Bone Metastases
- Head to Head, Prospective, Open Label Multicenter Study on the Diagnostic Efficacy of GPC3 Targeted PET Imaging and Enhanced Magnetic Resonance Imaging for Hepatocellular Carcinoma
- Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
- Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases
- Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
Stomach cancer
胃癌Led 136 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (3.9%).
- Open trials led
- 13
- Research papers it led
- 136
- Trials it led
- 36
- Share of China's trials
- 2.5%
- Share of the world's papers
- 0.7%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Impact of intraoperative explanation combined with surgical video review on anatomy learning in laparoscopic distal gastrectomy.
- Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer.
- The number of mesogastria containing metastatic lymph nodes predicts gastric cancer prognosis.
- Randomized clinical trial on D2 lymphadenectomy versus D2 lymphadenectomy plus complete mesogastric excision in patients undergoing gastrectomy for cancer (DCGC01 study).
- Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China.
Trials on ClinicalTrials.gov6
- Exploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Cohort Study
- CT Imaging and Clinical Features to Predict Outcomes in Patients With Gastric Cancer
- Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors
- Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors
- A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis
- Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Hepatoblastoma
肝母细胞瘤Led 2 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (13.6%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 1
- Share of China's trials
- 10.0%
- Share of the world's papers
- 0.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led2
Trials on ClinicalTrials.gov1
Retinoblastoma
视网膜母细胞瘤Led 6 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (12.0%).
- Open trials led
- 0
- Research papers it led
- 6
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.5%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Retinoblastoma and polydactyly in a child with 46, XY, 15pstk+ karyotype-A case report and literature review.
- UBE2C, Regulated by n6-methyladenosine Methyltransferase METTL3, Is an Oncogene in Retinoblastoma via PI3K-AKT Pathway.
- Gene expression study in retinoblastoma patients with different anaplasias and lateralities.
- Cordycepin inhibited the retinoblastoma cell proliferation, migration, and invasion as well as lung metastasis via modulating c-Myc/cyclin D1 pathway.
- miR-141-3p promotes retinoblastoma progression via inhibiting sushi domain-containing protein 2.
Chordoma
脊索瘤Led 2 of 105 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (23.8%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Osteosarcoma
骨肉瘤Led 49 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.3%).
- Open trials led
- 0
- Research papers it led
- 49
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.9%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Construction and clinical validation of a machine-learning-based consensus prognostic signature (MLPS) for osteosarcoma via multi-cohort data integration.
- Effects of Doxorubicin, Epirubicin, and Liposomal Doxorubicin (Anthracycline) on cardiac function in patients with osteosarcoma and their influencing factors.
- A very rare case of extraskeletal Ewing sarcoma of the duodenum presenting as gastrointestinal hemorrhage.
- Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies.
- Predictive value of preoperative platelet-to-albumin ratio and apolipoprotein B-to-apolipoprotein A1 ratio for osteosarcoma in children and adolescents: a retrospective study of 118 cases.
Gastrointestinal stromal tumour
胃肠道间质瘤Led 22 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.3%).
- Open trials led
- 1
- Research papers it led
- 22
- Trials it led
- 3
- Share of China's trials
- 4.0%
- Share of the world's papers
- 1.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Laparoscopic Versus Open Surgery for Rectal Gastrointestinal Stromal Tumor: A Multicenter Propensity Score-Matched Analysis.
- Is lymph node metastasis an advanced event of gastrointestinal stromal tumor?
- Distinguishing very high-risk patients among high-risk gastrointestinal stromal tumor cases: development and validation of a nomogram based on a multicenter population-based retrospective cohort study.
- Safety and feasibility of laparoscopy-assisted surgery for gastrointestinal stromal tumors larger than 5 cm: Results of a retrospective, single-center series of 1,802 consecutive patients.
- Clinicopathologic Characteristics and Prognosis of PDGFRA-Mutant Gastrointestinal Stromal Tumors: A Large-Scale, Multi-Institutional, Observational Study in China.
Trials on ClinicalTrials.gov6
- Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis
- Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- A Study of HQP1351 in Patients With GIST or Other Solid Tumors
- CEH-EUS for Differentiating GISTs and Leiomyomas: A Multicenter Prospective Self-Controlled Study
- A Real-world Comparison of FNB and FNA in IHC-required Lesions.
- A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
Neuroblastoma
神经母细胞瘤Led 22 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.8%).
- Open trials led
- 0
- Research papers it led
- 22
- Trials it led
- 1
- Share of China's trials
- 2.4%
- Share of the world's papers
- 0.5%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- β2-Microglobulin: A potential novel prognostic indicator for neuroblastoma.
- Leveraging small voxel with optimal acquisition time for [18F]mFBG total-body PET/CT imaging in pediatric patients with neuroblastoma: a preliminary study.
- Long-term survival outcomes of pediatric adrenal malignancies: An analysis with the upstaged SEER registry during 2000-2019.
- Distal-less homeobox 5 transactivated by MYCN contributes to progression of neuroblastoma through AKT signaling pathway.
- Targeting RBM10-Repressed RORB Activity in Liquid Condensates Inhibits Lysosomal Biogenesis and Neuroblastoma Progression via Affecting NF-κB Signaling.
Ewing sarcoma
尤文肉瘤Led 3 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.6%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
Trials on ClinicalTrials.gov1
Multiple myeloma
多发性骨髓瘤Led 50 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.8%).
- Open trials led
- 8
- Research papers it led
- 50
- Trials it led
- 15
- Share of China's trials
- 3.1%
- Share of the world's papers
- 0.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report.
- Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis.
- Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma.
- A successful haploidentical transplantation without conditioning regimen for a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T-cell therapy.
- Long-term safety and efficacy of the fully human CAR-T therapy CT103A in relapsed/refractory multiple myeloma.
Trials on ClinicalTrials.gov6
- A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
- A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.
- Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
- An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
- A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma
- The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial
B-cell acute lymphoblastic leukaemia (B-ALL)
B 细胞急性淋巴细胞白血病Led 11 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.9%).
- Open trials led
- 3
- Research papers it led
- 11
- Trials it led
- 8
- Share of China's trials
- 3.2%
- Share of the world's papers
- 1.0%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Bone marrow blasts- and modified EASIX-guided risk stratification for coagulopathy and outcomes after CAR-T therapy in relapsed/refractory B-ALL.
- Biomarkers for predicting CAR-T cell therapy outcomes in B-cell acute lymphoblastic leukemia: a systematic review.
- Novel Prognostic Scoring Systems for Severe CRS after Anti-CD19 CAR-T-Cells in Acute B-Lymphoblastic Leukemia.
- Blinatumomab in pediatric B-acute lymphoblastic leukemia.
- Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed/refractory B cell acute lymphoblastic leukemia.
Trials on ClinicalTrials.gov6
- A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults
- JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
- CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
- Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
- Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
- Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
Aplastic anaemia
再生障碍性贫血Led 10 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (17.2%).
- Open trials led
- 1
- Research papers it led
- 10
- Trials it led
- 2
- Share of China's trials
- 2.1%
- Share of the world's papers
- 0.6%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Parvovirus B19-induced aplastic anemia following mechanical valve replacement.
- Comparison of Haploidentical-Hematopoietic Stem Cell Transplantation Using Modified Post-Transplantation Cyclophosphamide and Eltrombopag Combined With Immunosuppression for the Treatment of Severe Aplastic Anemia.
- An atypical patient with bone marrow failure syndrome-2 without microcephaly and learning disability in a Chinese family.
- Comparisons of Modified Post-Transplantation Cyclophosphamide and Granulocyte Colony-Stimulating Factor/Antithymocyte Globulin Regimens for Haploidentical Stem Cell Transplantation in Patients with Aplastic Anemia.
- A New Immunosuppressive Therapy for Very Severe Aplastic Anemia in Children with Autoantibodies.
Trials on ClinicalTrials.gov2
Haemophagocytic lymphohistiocytosis (HLH)
噬血细胞性淋巴组织细胞增生症Led 28 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (22.3%).
- Open trials led
- 1
- Research papers it led
- 28
- Trials it led
- 1
- Share of China's trials
- 2.1%
- Share of the world's papers
- 1.7%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Deep insight into cytokine storm: from pathogenesis to treatment.
- UNC13D c.2588G>A Nucleotide Variant Impairs NK-Cell Cytotoxicity in Adult-Onset EBV-Associated Hemophagocytic Lymphohistiocytosis: A Pedigree Study.
- Unveiling fatal risk factors: Predicting hemophagocytic lymphohistiocytosis in SFTS patients.
- A case of cirrhosis concurrent with NK/T-Cell lymphoma and hemophagocytic lymphohistiocytosis: a clinical report and literature review.
- Development and validation of a predictive model for diagnosing EBER-positive lymphoma-associated hemophagocytic lymphohistiocytosis.
Trials on ClinicalTrials.gov2
- Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection
- A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
Haemophilia A
血友病 ALed 5 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (15.8%).
- Open trials led
- 0
- Research papers it led
- 5
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Clinical Analysis and Mental Health Survey of Hemophilia Carriers: a Cross-sectional Study.
- An aberrant F8 intron 1 inversion with concomitant large duplication and deletion in a Chinese severe hemophilia A patient.
- RNAi targeting heparin cofactor II promotes hemostasis in a canine model of acquired hemophilia A.
- Investigation and Analysis of the Current Status of Health-Related Quality of Life in Adolescents with Hemophilia in Hubei Province.
- TWIN BROTHERS WITH VARIABLE PHENOTYPES OF HAEMOPHILIA A RESULTING FROM MATERNAL MOSAICISM OF ARG550CYS OF F8.
Trials on ClinicalTrials.gov6
- To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
- Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
- A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
- Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A
- Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.
Thrombotic thrombocytopenic purpura
血栓性血小板减少性紫癜Led 6 of 64 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (9.4%).
- Open trials led
- 0
- Research papers it led
- 6
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.8%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Improving the PLASMIC score with the use of RDW-SD in the differential diagnosis for thrombotic thrombocytopenic purpura in Chinese patients.
- Prognostic value of laboratory biomarkers for mortality risk stratification in thrombotic thrombocytopenic purpura.
- A Novel Variant on the Thrombospondin Type-1 Repeat 2 Domain of ADAMTS13 in a Parturient with Suspected Hereditary Thrombotic Thrombocytopenic Purpura and Unusually High ADAMTS13 Activity.
- A Case of Parturient with Hereditary Thrombotic Thrombocytopenic Purpura: Case Report of a Novel Variant.
- Thrombotic thrombocytopenic purpura complicated with acute aortic dissection: A case report.
Trials on ClinicalTrials.gov1
Neuromyelitis optica spectrum disorder (NMOSD)
视神经脊髓炎谱系疾病Led 19 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.5%).
- Open trials led
- 7
- Research papers it led
- 19
- Trials it led
- 8
- Share of China's trials
- 10.3%
- Share of the world's papers
- 1.0%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Quantitative Contribution of Clinical Attacks to Residual Disability in Patients With AQP4-Antibody Neuromyelitis Optica Spectrum Disorder.
- Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results.
- Soluble TREM2 triggers microglial dysfunction in neuromyelitis optica spectrum disorders.
- Astrocyte-Derived Exosomes Contribute to Pathologies of Neuromyelitis Optica Spectrum Disorder in Rodent Model.
- Comparison of clinical and radiological characteristics in autoimmune GFAP astrocytopathy, MOGAD and AQP4-IgG+ NMOSD mimicking intracranial infection as the initial manifestation.
Trials on ClinicalTrials.gov6
- Tongji NADs Cohort
- Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
- Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD
- The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
- Biomarkers in Autoimmune Disease of Nervous System
- Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)
IgG4-related disease
IgG4相关性疾病Led 13 of 246 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (19.1%).
- Open trials led
- 2
- Research papers it led
- 13
- Trials it led
- 4
- Share of China's trials
- 9.3%
- Share of the world's papers
- 1.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Thalidomide can effectively prevent relapse in IgG4-related disease outweighing its side effects: a multicentre, randomised, double-blinded, placebo-controlled study.
- BLyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept.
- Multi-System Langerhans Cell Histiocytosis as a Mimic of IgG4-Related Disease: A Case Report and Literature Review.
- Clinical value of 18F-FDG PET/CT in IgG4-related disease.
- IgG4-Related Disease: A Retrospective Chinese Study of Features and Treatment Response of 98 Patients Including 4 Rare Cases.
Trials on ClinicalTrials.gov6
- Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
- Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
- Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
- A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases
- the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases
- A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
Myasthenia gravis
重症肌无力Led 17 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.6%).
- Open trials led
- 9
- Research papers it led
- 17
- Trials it led
- 11
- Share of China's trials
- 12.0%
- Share of the world's papers
- 0.8%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Perioperative Efgartigimod treatment for acute myasthenia gravis exacerbation with retroperitoneal mass: a case report.
- Long-term efficacy and safety of tacrolimus in anti-MuSK antibody-positive myasthenia gravis: a retrospective single-center cohort study.
- Exhausted signature and regulatory network of NK cells in myasthenia gravis.
- Clinical Features, Treatment, and Prognostic Factors of Childhood-Onset Myasthenia Gravis in a Large Chinese Cohort.
- Clinical and immune-related factors associated with exacerbation in adults with well-controlled generalized myasthenia gravis.
Trials on ClinicalTrials.gov6
- Tongji NADs Cohort
- Universal STAR-T Cell Injection in Generalized Myasthenia Gravis
- Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
- Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
- A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Refractory Generalized Myasthenia Gravis
- CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Moyamoya disease
烟雾病Led 5 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (19.9%).
- Open trials led
- 1
- Research papers it led
- 5
- Trials it led
- 1
- Share of China's trials
- 3.0%
- Share of the world's papers
- 0.4%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Comparative study on acute management of intracerebral haematoma using local thrombolysis in moyamoya and non-moyamoya patients: a single institution experience.
- Progress in the application of stem cell therapy for moyamoya disease.
- Identification of the potential role of S1PR1 in adult moyamoya disease based on multiple bioinformatics analysis and experimental verification.
- Endothelial Cell-Derived Let-7c-Induced TLR7 Activation on Smooth Muscle Cell Mediate Vascular Wall Remodeling in Moyamoya Disease.
- CircZXDC Promotes Vascular Smooth Muscle Cell Transdifferentiation via Regulating miRNA-125a-3p/ABCC6 in Moyamoya Disease.
Trials on ClinicalTrials.gov1
Biliary atresia
胆道闭锁Led 10 of 214 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (9.8%).
- Open trials led
- 1
- Research papers it led
- 10
- Trials it led
- 2
- Share of China's trials
- 10.0%
- Share of the world's papers
- 1.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Diagnostic performance and reproducibility of shear wave elastography techniques for liver stiffness assessment in children with biliary atresia.
- Efficacy of sodium bicarbonate Ringer's solution for perioperative fluid management in infants with biliary atresia: a prospective multicenter study.
- Comparison of surgical results and technical performance between robotic and laparoscopic approaches for Kasai portoenterostomy in biliary atresia: a multicenter retrospective study.
- Comparison between robotic-assisted Kasai portoenterostomy and open Kasai portoenterostomy in patients with biliary atresia.
- Robotic-assisted Kasai portoenterostomy for biliary atresia.
Trials on ClinicalTrials.gov2
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 4 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.2%).
- Open trials led
- 0
- Research papers it led
- 4
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Catatonia in adult anti-NMDAR encephalitis: an observational cohort study.
- Anti-N-methyl-D-aspartate receptor encephalitis associated with chronic myelogenous leukemia, causality or coincidence? A case report.
- Decoding NMDAR encephalitis: proteomic markers and computational identification of potential therapeutic pathways.
- Intrathecal treatment of Anti-N-Methyl-D-Aspartate receptor encephalitis: a promising approach for refractory cases.
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 23 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.3%).
- Open trials led
- 0
- Research papers it led
- 23
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.6%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Associations between dietary patterns and the incidence of idiopathic pulmonary fibrosis: A cohort study.
- Imaging Pulmonary Fibrosis and Treatment Efficacy In Vivo with Autotaxin-Specific PET Ligand [18F]ATX-1905.
- A nonsynonymous polymorphism (rs117179004, T392M) of hyaluronidase 1 (HYAL1) is associated with increased risk of idiopathic pulmonary fibrosis in Southern Han Chinese.
- Six1 promotes alveolar epithelium senescence in pulmonary fibrosis through regulating Tp53.
- Targeting PBK in the fibroblast-to-myofibroblast transition: A novel therapeutic strategy for IPF.
Trials on ClinicalTrials.gov6
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 15 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.3%).
- Open trials led
- 1
- Research papers it led
- 15
- Trials it led
- 1
- Share of China's trials
- 1.8%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Cd16-Cd56bright NK Cells: A Protective NK Cell Subset for Progression and Prognosis in Amyotrophic Lateral Sclerosis.
- Association between apathy and caregiver burden in patients with amyotrophic lateral sclerosis: a cross-sectional study.
- Quantitative MRI Analysis of Brachial Plexus and Limb-Girdle Muscles in Upper Extremity Onset Amyotrophic Lateral Sclerosis.
- Astrocytes Contribute to Motor Neuron Degeneration in ALS via the TRAIL-DR5 Signaling Pathway.
- Cryptic Splicing of GAP43 mRNA is a Novel Hallmark of TDP-43-Associated ALS and AD.
Trials on ClinicalTrials.gov1
Duchenne muscular dystrophy
杜氏肌营养不良Led 4 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.8%).
- Open trials led
- 0
- Research papers it led
- 4
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Identifying inversions with breakpoints in the Dystrophin gene through long-read sequencing: report of two cases.
- ARC-18 Improved Motor Performance Through Inhibiting ACLY-Mediated Smad2/3 Acetylation in a Model of Duchenne Muscular Dystrophy.
- Long-term effect of human mini-dystrophin in transgenic mdx mice improves muscle physiological function.
- Cardiac Phenotype-Genotype Associations in DMD/BMD: A Meta-Analysis and Systematic Review.
Behçet disease
白塞病Led 2 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (22.9%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Alport syndrome
Alport 综合征Led 3 of 58 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (17.2%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.8%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Pathogenic synonymous variation of the COL4A3 gene causing Alport syndrome comorbid with IgA deposition in a toddler: a case report.
- Clinical, histological and molecular characteristics of Alport syndrome in Chinese children.
- Gross hematuria, edema, and hypocomplementemia in a 9-year-old boy: Answers.
Trials on ClinicalTrials.gov1
IgA nephropathy
IgA 肾病Led 23 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (9.4%).
- Open trials led
- 1
- Research papers it led
- 23
- Trials it led
- 3
- Share of China's trials
- 2.5%
- Share of the world's papers
- 1.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Prognosis and predictive factors in pediatric IgA nephropathy.
- Efficacy and Safety of Telitacicept in IgA Nephropathy and IgA Vasculitis-Associated Nephritis in Children: A Retrospective Single-Centre Study.
- Development and Validation of a Predictive Model for Severe Tubular Atrophy/Interstitial Fibrosis in Patients with IgA Nephropathy: Multicenter Retrospective Study.
- Efficacy and safety of telitacicept in children with IgA vasculitis and IgA vasculitis nephritis: a single-center retrospective study.
- Pathogenic synonymous variation of the COL4A3 gene causing Alport syndrome comorbid with IgA deposition in a toddler: a case report.
Trials on ClinicalTrials.gov5
- A Study of YKST02 in Participants With Primary IgA Nephropathy
- Efficacy and Safety of Probiotics Combined With Enteric-coated Budesonide Capsules in Patients With Primary IgA Nephropathy
- Model Development and Application Based on Renal Pathology Images
- TESTING -ON Post-Trial ObservatioNal Cohort Study
- Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)
Primary biliary cholangitis
原发性胆汁性胆管炎Led 5 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (12.0%).
- Open trials led
- 0
- Research papers it led
- 5
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Evaluating the diagnostic efficacy of anti-M2-3E, anti-gp210, and anti-sp100 antibodies in primary biliary cirrhosis.
- A Phenome-Wide Mendelian Randomization and Colocalization Study Reveals Genetic Association Between PBC and Other Autoimmune Disorders.
- Dysregulation and impaired anti-bacterial potential of mucosal-associated invariant T cells in autoimmune liver diseases.
- The HSP90 inhibitor 17-DMAG alleviates primary biliary cholangitis via cholangiocyte necroptosis prevention.
- Prevalence and impact of Sjögren's syndrome in primary biliary cholangitis: a systematic review and meta-analysis.
Trials on ClinicalTrials.gov4
- Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
- A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
- Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis
Hirschsprung disease
先天性巨结肠Led 21 of 161 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (13.0%).
- Open trials led
- 0
- Research papers it led
- 21
- Trials it led
- 5
- Share of China's trials
- 41.7%
- Share of the world's papers
- 2.8%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Analysis of the causes of redo pull-through for recurrent constipation and the risk factors affecting the prognosis of the Hirschsprung's disease: a single-center retrospective study and systematic review.
- Rare and common genetic variants underlying the risk of Hirschsprung's disease.
- Whole-genome sequencing identified ALK as a novel susceptible gene of Hirschsprung disease.
- Robotic-assisted Proctosigmoidectomy Versus Laparoscopic-assisted Soave Pull-through for Hirschsprung Disease: Medium-term Outcomes From a Prospective Multicenter Study.
- Robotic-assisted proctosigmoidectomy for Hirschsprung's disease: A multicenter prospective study.
Trials on ClinicalTrials.gov5
- Nutrition Support for Hirschsprung Disease
- A Trial on Treatments of Hirschsprung Allied Disease
- Comparison of Circular(Soave) and Heart-shaped Anastomosis in Hirschsprung's Disease
- Fast-track Surgery in the Treatment of Hirschsprung's Disease
- A New Scoring System Improves Diagnostic Accuracy of Intestinal Dysganglionosis --a Prospective Study
Hereditary angioedema
遗传性血管性水肿Led 1 of 32 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (31.2%).
- Open trials led
- 0
- Research papers it led
- 1
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led1
Familial adenomatous polyposis
家族性腺瘤性息肉病Led 0 of 59 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.2%).
- Open trials led
- 0
- Research papers it led
- 0
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.0%
Leber hereditary optic neuropathy
Leber 遗传性视神经病变Led 2 of 52 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (21.1%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 2
- Share of China's trials
- 40.0%
- Share of the world's papers
- 0.6%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.